EUVIMEDEUVIMED entdecken
Open Access · CC BY 2.0

Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans

Emanuela Palmerini, Marco Gambarotti, Eric L Staals, Licciana Zanella, Gabriela Sieberova, Alessandra Longhi, Marilena Cesari, Stefano Bonarelli, Piero Picci, Pietro Ruggieri, Marco Alberghini, Stefano Ferrari

Clinical Sarcoma Research · 2012-12 · 2 (1)

DOI: 10.1186/2045-3329-2-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Sarcoma Research, online erschienen am 27.01.2012. Verfasst von Emanuela Palmerini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, via Pupilli 1, Bologna, 40136, Italy. emanuela.palmerini@ior.it. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a relatively common soft-tissue tumor. A more aggressive appearing fibrosarcoma may arise in DFSP, changing its biological behavior. CD34 and apolipoprotein-D are highly expressed in DFSP, but their prognostic significance is uncertain. METHODS: DFSP and fibrosarcomatous-DFSP (FS-DFSP) patients referred to our institute between 1982 and 2009 were identified. Fibrosarcomatous changes, expression of CD34 and apolipoprotein-D were evaluated. RESULTS: 40 patients, (median age 43 years, 55% males) were identified. Tumor was located in the limbs in 60%, in the trunk in 40%. Thirty-seven patients had localized and 3 had metastatic disease. Thirteen (32%) patients were FS-DFSP. All but one underwent surgery with adequate surgical margins in 72%. 7 FS-DFSP received also radiotherapy (RT). Chemotherapy was administered to 3 patients with FS-DFSP. With a median follow-up of 49 months, the 5-OS was 90%. Local recurrence rate was 23%: 42% FS-DFSP, 15% DFSP. Metastases developed in three FS-DFSP patients. The 5-year EFS was 70% in localized patients. Histology (DFSP 75% vs. FS-DFSP 52%, p = 0.002), surgical margins (adequate 74% vs. inadequate 55%, p = 0.02), site (limb 47% vs. trunk 100%), CD34 expression (CD34 positive: 70% vs. CD34 negative: 33%, p = 0.05), and apolipoprotein-D expression (Apo-D positive: 73% vs. Apo-D negative: 33%, p = 0.02) influenced the 5-year EFS, whereas sex, use of RT or number of previous surgical treatments did not. CONCLUSIONS: Patients with DFSP have a high survival probability. Site, adequate surgical margins, presence of the fibrosarcomatous component, lack of CD34 expression and apolipoprotein-D influence outcome.

Autor:innen und Institutionen

  • Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, via Pupilli 1, Bologna, 40136, Italy. emanuela.palmerini@ior.it.

Zitieren

APA

Palmerini, E., Gambarotti, M., Staals, E. L., Zanella, L., Sieberova, G., Longhi, A., Cesari, M., Bonarelli, S., Picci, P., Ruggieri, P., Alberghini, M., & Ferrari, S. (2012). Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. Clinical Sarcoma Research, 2(1). https://doi.org/10.1186/2045-3329-2-4

Vancouver

Palmerini E, Gambarotti M, Staals EL, Zanella L, Sieberova G, Longhi A, et al. Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. Clinical Sarcoma Research. 2012;2(1). doi:10.1186/2045-3329-2-4

BibTeX
@article{Palmerini2012,
  author = {Palmerini, Emanuela and Gambarotti, Marco and Staals, Eric L and Zanella, Licciana and Sieberova, Gabriela and Longhi, Alessandra and Cesari, Marilena and Bonarelli, Stefano and Picci, Piero and Ruggieri, Pietro and Alberghini, Marco and Ferrari, Stefano},
  title = {Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans},
  journal = {Clinical Sarcoma Research},
  year = {2012},
  volume = {2},
  number = {1},
  doi = {10.1186/2045-3329-2-4}
}
Kostenlos starten →